Gilead Sciences (GILD) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Gilead Sciences (GILD) is Neutral.

The composite score behind that read is +0.18, weighing +0.24 of bullish evidence against -0.12 bearish.

Gilead Sciences last closed at $151.17, +2.77% on the session.

Against the IVW growth benchmark the position is +1.97% over the forecast window.

The read is built from 15 underlying insights — 8 bullish and 7 bearish.

Agreement across those insights is 53%.

4 graded predictions for GILD so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Gilead Sciences in the 29th percentile on return on equity, where 100 is best.

Gilead Sciences is classified under Health Care / Biotechnology, with a market capitalisation of $182.40B.

StockMap tracks Gilead Sciences as the 3rd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Gilead Sciences ranks 20th of 381 in the group, against a group median of -0.08.